News | August 07, 2012

Navidea Biopharmaceuticals Licenses Parkinson's Imaging Agent

Licensing adds second promising neuroimaging candidate to Navidea pipeline

August 7, 2012 — Navidea Biopharmaceuticals Inc., a company focused on precision diagnostic radiopharmaceuticals, announced it has entered into an agreement with Alseres Pharmaceuticals Inc. to license [123I]-E-IACFT Injection (CFT), an iodine-123 radio-labeled imaging agent being developed as an aid in the diagnosis of Parkinson’s disease and other movement disorders, with a potential use as a diagnostic aid in dementia.

CFT is a patented, novel, small molecule radiopharmaceutical used with single photon emission computed tomography (SPECT) imaging to identify the status of specific regions in the brains of patients suspected of having Parkinson’s disease. The agent binds to the dopamine transporter (DAT) on the cell surface of dopaminergic neurons in the striatum and substantia nigra regions of the brain. Loss of these neurons is a widely recognized hallmark of Parkinson’s disease.

CFT has been administered to more than 600 subjects in multiphase clinical trials to date. Results from these clinical trials have demonstrated that CFT has high affinity for DAT and rapid kinetics that enable the generation of clean diagnostic images quickly, beginning within approximately 20 minutes after injection. In addition to its potential use as an aid in the differential diagnosis of Parkinson’s disease and movement disorders, CFT may also be useful in the diagnosis of dementia with Lewy bodies (DLB), which, after Alzheimer’s disease, is one of the most common forms of dementia.

“The diagnostic dilemma in movement disorders remains a pressing medical need that will continue to escalate as our world’s population ages,” said Mark Pykett, president and CEO of Navidea. “The addition of the CFT program is consistent with our growth strategy to build our precision radiopharmaceutical pipeline with later-stage, high-value diagnostics aimed at important medical needs.”

“We believe that CFT has the potential to be a best-in-class imaging agent to improve diagnostic accuracy by differentiating Parkinson’s disease from non-degenerative movement disorders, especially during the period soon after symptom-onset,” said Thomas Tulip, executive vice president and chief business officer at Navidea. “This licensing agreement has afforded Navidea another strong Phase 3 diagnostic imaging asset that has great synergy with our AZD4694 imaging program, which we are developing as an aid in the diagnosis of Alzheimer’s disease. These exciting programs provide us with a robust franchise in precision neuroimaging diagnostics.”

Under the terms of the license agreement, Alseres granted Navidea an exclusive, worldwide sub-license to research, develop and commercialize CFT. The final terms of the agreement call for Navidea to make a one-time sub-license execution payment to Alseres equal to $175,000 and issue Alseres 300,000 shares of NAVB common stock.

For more information: www.navidea.com

Related Content

Technology | Neuro Imaging | December 07, 2017
Deep learning artificial intelligence (AI) medical company DeepRadiology  announced the world's first computed...
Brain's Appetite Regulator Disrupted in Obese Teens
News | Neuro Imaging | December 05, 2017
December 5, 2017 — Advanced...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Study Unveils Brain Changes During Extended Space Missions
News | Neuro Imaging | November 14, 2017
November 14, 2017 — More people today are poised to explore space than ever before; those who do will experience the
Post-Concussion Brain Changes Persist for Pre-Teen Hockey Players
News | Magnetic Resonance Imaging (MRI) | November 02, 2017
Young hockey players who have suffered concussions may still show changes in the white matter of the brain months after...
Football Position and Length of Play Affect Brain Impact
News | Magnetic Resonance Imaging (MRI) | October 31, 2017
Researchers have found that damage to white matter in the brains of former college and professional football players...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Study Creates Navigational View of the Brain With X-ray Tomography

A "navigational map view" of a section of a mouse brain. Like the map view of an Earth imaging program, this image of a brain section takes cues from actual imaging performed with highest-energy X-rays at a synchrotron and turns them into a graphic depiction. The imaging concentrates on a mesa-scale of the brain analogous to the map view of Google Earth. The scale could be useful in studying how the brain computes. Cell bodies in gray and blue; vasculature in red. Image courtesy of Georgia Tech/Eva Dyer.

News | Neuro Imaging | October 26, 2017
A research team led by Eva Dyer, a computational neuroscientist and electrical engineer, has successfully imaged brains...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Overlay Init